AU2001286965A1 - Sodium channel modulators - Google Patents
Sodium channel modulatorsInfo
- Publication number
- AU2001286965A1 AU2001286965A1 AU2001286965A AU8696501A AU2001286965A1 AU 2001286965 A1 AU2001286965 A1 AU 2001286965A1 AU 2001286965 A AU2001286965 A AU 2001286965A AU 8696501 A AU8696501 A AU 8696501A AU 2001286965 A1 AU2001286965 A1 AU 2001286965A1
- Authority
- AU
- Australia
- Prior art keywords
- sodium channel
- channel modulators
- modulators
- sodium
- channel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108010052164 Sodium Channels Proteins 0.000 title 1
- 102000018674 Sodium Channels Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
- C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
- C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
- C07C217/20—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22957200P | 2000-08-31 | 2000-08-31 | |
US60/229,572 | 2000-08-31 | ||
PCT/US2001/027128 WO2002018334A2 (fr) | 2000-08-31 | 2001-08-30 | Modulateurs du canal sodique |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001286965A1 true AU2001286965A1 (en) | 2002-03-13 |
Family
ID=22861810
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001286965A Abandoned AU2001286965A1 (en) | 2000-08-31 | 2001-08-30 | Sodium channel modulators |
Country Status (3)
Country | Link |
---|---|
US (2) | US6756400B2 (fr) |
AU (1) | AU2001286965A1 (fr) |
WO (1) | WO2002018334A2 (fr) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002236775A1 (en) * | 2001-01-16 | 2002-07-30 | Seok-Ki Choi | Sodium channel modulators |
EP1589959A2 (fr) * | 2003-01-30 | 2005-11-02 | Dynogen Pharmaceuticals Inc. | Methodes destinees a traiter les troubles du tractus urinaire inferieur au moyen de modulateurs du canal sodique |
AU2004207009A1 (en) * | 2003-01-30 | 2004-08-12 | Dynogen Pharmaceuticals, Inc. | Use of sodium channel modulators for treating gastrointestinal tract disorders |
CA2533392A1 (fr) * | 2003-07-24 | 2005-02-03 | Merck & Co., Inc. | Cycloalcanes diphenyl-substitutes, compositions contenant ces composes, et procedes d'utilisation |
US7125908B2 (en) * | 2003-08-29 | 2006-10-24 | Allergan, Inc. | Treating pain using selective antagonists of persistent sodium current |
US7060723B2 (en) | 2003-08-29 | 2006-06-13 | Allergan, Inc. | Treating neurological disorders using selective antagonists of persistent sodium current |
WO2005097087A2 (fr) * | 2004-04-01 | 2005-10-20 | Cardiome Pharma Corp. | Composes combines de modulation du canal ionique et utilisation desdits composes |
WO2005113011A2 (fr) | 2004-04-01 | 2005-12-01 | Cardiome Pharma Corp. | Promedicaments de composes modulant les canaux ioniques et leurs utilisations |
WO2005108337A2 (fr) * | 2004-05-04 | 2005-11-17 | Acadia Pharmaceuticals Inc. | Composes presentant une activite sur le recepteur des oestrogenes |
US7825265B2 (en) | 2004-05-04 | 2010-11-02 | Acadia Pharmaceuticals Inc. | Compounds with activity at estrogen receptors |
WO2005115367A2 (fr) * | 2004-05-20 | 2005-12-08 | The Regents Of The University Of California | Modulation de l'activite des neurotransmetteurs dans les neurones |
US7531523B2 (en) * | 2005-02-17 | 2009-05-12 | Vertex Pharmaceuticals Incorporated | Sodium channel protein type III alpha-subunit splice variant |
AU2006223508A1 (en) * | 2005-03-09 | 2006-09-21 | Merck Frosst Canada Ltd | Diphenyl substituted cycloalkanes, compositions containing such compounds and methods of use |
WO2007086895A2 (fr) * | 2005-03-22 | 2007-08-02 | Pinnacle Pharmaceuticals | Composes antibacteriens et leurs utilisations |
US20080200408A1 (en) * | 2005-09-30 | 2008-08-21 | Mccormack Kenneth | Deletion mutants of tetrodotoxin-resistant sodium channel alpha subunit |
US7972813B2 (en) * | 2005-09-30 | 2011-07-05 | Vertex Pharmaceuticals Incorporated | Tetrodotoxin-resistant sodium channel alpha subunit |
WO2007073407A1 (fr) * | 2005-12-21 | 2007-06-28 | Decode Genetics Ehf | Inhibiteurs heterocycliques de lta4h a substitution biaryl, contenant de l'azote, destines au traitement d'inflammations |
BRPI0913673A2 (pt) * | 2008-07-02 | 2015-10-13 | British Columbia Cancer Agency | uso de um composto, composição farmacêutica, e, método para modular a atividade do receptor de andrógeno |
AR079975A1 (es) * | 2010-01-06 | 2012-03-07 | British Columbia Cancer Agency | Agentes terapeuticos derivados de bisfenol u metodos para su uso, composiciones farmaceuticas y uso de los mismos |
JP5940982B2 (ja) | 2010-01-06 | 2016-06-29 | ブリティッシュ コロンビア キャンサー エージェンシー ブランチ | アンドロゲンレセプター活性調節因子としての、ビスフェノール誘導体およびその使用 |
US9365510B2 (en) | 2012-04-16 | 2016-06-14 | British Columbia Cancer Agency Branch | Aziridine bisphenol ethers and related compounds and methods for their use |
CA2941171C (fr) * | 2013-03-04 | 2020-07-07 | Purdue Pharma L.P. | Pyrimidine carboxamides a titre de bloqueurs des canaux sodiques |
KR20170060162A (ko) | 2013-05-10 | 2017-05-31 | 브리티쉬 콜롬비아 캔써 에이전시 브랜치 | 안드로겐 수용체 조절제의 에스터 유도체 및 그의 이용 방법 |
KR20160054523A (ko) | 2013-09-09 | 2016-05-16 | 브리티쉬 콜롬비아 캔써 에이전시 브랜치 | 암 영상화 및 치료용 할로겐화 화합물, 및 이들의 사용 방법 |
EP3988541B1 (fr) | 2015-01-13 | 2024-06-26 | British Columbia Cancer Agency Branch | Composés hétérocycliques pour l'imagerie et le traitement du cancer et leurs procédés d'utilisation |
US10471023B2 (en) | 2015-03-12 | 2019-11-12 | British Columbia Cancer Agency Branch | Bisphenol ether derivatives and methods for using the same |
US20170298033A1 (en) | 2016-04-15 | 2017-10-19 | The University Of British Columbia | Bisphenol derivatives and their use as androgen receptor activity modulators |
WO2019226991A1 (fr) | 2018-05-25 | 2019-11-28 | Essa Pharma, Inc. | Modulateurs du récepteur des androgènes et leurs procédés d'utilisation |
US20200123117A1 (en) | 2018-10-18 | 2020-04-23 | Essa Pharma, Inc. | Androgen receptor modulators and methods for their use |
US20210323931A1 (en) | 2020-04-17 | 2021-10-21 | Essa Pharma, Inc. | Solid forms of an n-terminal domain androgen receptor inhibitor and uses thereof |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1219039B (de) * | 1959-09-26 | 1966-06-16 | Bayer Ag | Verfahren zur Herstellung von primaeren Diaminen |
US3197434A (en) | 1960-03-17 | 1965-07-27 | Monsanto Co | Polycarbonamides from organic dicarboxylic acids and bis(aminopropoxyaryl)alkanes and process for producing the same |
FR150M (fr) | 1963-07-24 | 1961-01-20 | Corbiere Et Pansements Brevete | Nouveau produit a action anesthésique locale. |
US3247199A (en) | 1961-01-27 | 1966-04-19 | Ciba Geigy Corp | Diphenyl-methanes |
BE613143A (fr) | 1961-01-27 | 1962-07-26 | Ciba Geigy | Nouveaux phénoxy-éthers et procédé pour leur préparation |
US3340146A (en) | 1964-04-27 | 1967-09-05 | Ciba Geigy Corp | Taeniacidal compositions of bis-arylsulfides |
US3449418A (en) * | 1965-12-22 | 1969-06-10 | Ciba Geigy Corp | Etherified bisaryl compounds |
US3598866A (en) | 1969-06-16 | 1971-08-10 | Dow Chemical Co | Adducts of alkenyl isocyanates with bisphenol a and derivatives thereof |
US4008265A (en) | 1971-05-22 | 1977-02-15 | Sumitomo Chemical Company, Limited | Novel bisphenoxy carboxylic acid derivatives and their salts |
JPS557861B2 (fr) * | 1972-10-04 | 1980-02-28 | ||
GB1584428A (en) * | 1976-08-31 | 1981-02-11 | Lilly Co Eli | Herbicides |
JPH06239815A (ja) * | 1993-02-16 | 1994-08-30 | Teijin Ltd | 2―アミノエトキシベンゼン誘導体及び医薬組成物 |
GB9403639D0 (en) * | 1994-02-25 | 1994-04-13 | Boots Co Plc | Therapeutic agents |
US5688830A (en) * | 1996-01-25 | 1997-11-18 | Syntex (U.S.A.) Inc. | Treatment of neuropathic pain |
CA2232147A1 (fr) * | 1997-04-03 | 1998-10-03 | F. Hoffmann-La Roche Ag | Derives de la phenoxymethylpiperidine |
US6579328B2 (en) * | 2000-05-01 | 2003-06-17 | Ciba Specialty Chemicals Corporation | Transition-metal-catalyzed process for the preparation of sterically hindered N-substituted aryloxyamines |
-
2001
- 2001-08-30 AU AU2001286965A patent/AU2001286965A1/en not_active Abandoned
- 2001-08-30 US US09/943,420 patent/US6756400B2/en not_active Expired - Lifetime
- 2001-08-30 WO PCT/US2001/027128 patent/WO2002018334A2/fr active Application Filing
-
2004
- 2004-04-15 US US10/824,738 patent/US7183323B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US20040204460A1 (en) | 2004-10-14 |
WO2002018334A3 (fr) | 2002-06-13 |
WO2002018334B1 (fr) | 2002-09-26 |
US6756400B2 (en) | 2004-06-29 |
WO2002018334A2 (fr) | 2002-03-07 |
US20030027822A1 (en) | 2003-02-06 |
US7183323B2 (en) | 2007-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001286965A1 (en) | Sodium channel modulators | |
AU2001276031A1 (en) | Branded channel | |
AU2001253535A1 (en) | Channel dancer | |
AU2002231325A1 (en) | Stat modulators | |
AU2001264879A1 (en) | Electrochromic devices | |
AU2001281997A1 (en) | Glazing | |
AU2001287983A1 (en) | Seal system | |
AU2002236775A1 (en) | Sodium channel modulators | |
AU2000235960A1 (en) | Lxr modulators | |
AU2001295758A1 (en) | Seal | |
AU2001210076A1 (en) | Ferrule seal | |
AU2001291854A1 (en) | Antibacterials mutilins | |
AU4537400A (en) | Ion channel modulating agents | |
EP1368891B8 (fr) | Modulateur iq | |
AU2001266204A1 (en) | Eyewear | |
AU2001265329A1 (en) | Enhanced channel adapter | |
HUP0600032A2 (en) | Sodium channel modulators derived from 2-piperidylimidazoles | |
AU5028201A (en) | Seal arrangement | |
AU2001223878A1 (en) | Sealant | |
AU4620300A (en) | Can | |
AU2002221890A1 (en) | Effect light | |
AU4087401A (en) | Communications | |
AU2001256507A1 (en) | Modulation | |
AU2001272594A1 (en) | Sealing arrangement | |
AU2001267554A1 (en) | Glazing |